Cell Source, Inc. (CLCS) intrinsic value & 10-year financials
Cell Source, Inc. (CLCS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.46
- Market cap
- $19.5M
- Revenue (FY2024)
- —
- ROIC (10-yr avg)
- 44.8%
- Free cash flow (FY2024)
- —
CLCS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$4.5M | -$0.14 | — | — | 26.4% |
| FY2023 | — | -$5.3M | -$0.17 | — | — | 37.7% |
| FY2022 | — | -$5.2M | -$0.18 | — | — | 46.0% |
| FY2021 | — | -$5.5M | -$0.19 | — | — | 61.6% |
| FY2020 | — | -$4.6M | — | — | — | 53.2% |
| FY2019 | — | -$4.5M | — | — | — | 73.2% |
| FY2018 | — | -$2.1M | — | — | — | 43.4% |
| FY2017 | — | -$3.1M | — | — | — | 47.0% |
| FY2016 | — | -$967.8K | — | — | — | 16.1% |
| FY2015 | — | -$2.5M | — | — | — | 43.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cell Source, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cell Source, Inc. has earned high returns on invested capital, averaging 44.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Cell Source, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Cell Source, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.